Pfizer Recommends Suffixes for Biosimilar Reference Products

Drug Industry Daily
A A
Pfizer is calling on the FDA to retroactively assign four-letter suffixes to biologics that act as reference products for innovative biosimilars.

To View This Article:

Login

Subscribe To Drug Industry Daily